Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

被引：2
|
作者：
Usmani, S. Z. [1 ]
Hoering, A. [2 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Canc Res & Biostat, Seattle, WA USA
来源：
LEUKEMIA | 2013年 / 27卷 / 12期
关键词：
TOTAL THERAPY 3; MULTIPLE-MYELOMA; BORTEZOMIB; DELETION;
D O I：
10.1038/leu.2013.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2269 / 2271
页数：3
相关论文
共 50 条
  • [41] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
    Alsina, Melissa
    Trudel, Suzanne
    Furman, Richard R.
    Rosen, Peter J.
    O'Connor, Owen A.
    Comenzo, Raymond L.
    Wong, Alvin
    Kunkel, Lori A.
    Molineaux, Christopher J.
    Goy, Andre
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4830 - 4840
  • [42] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    Jakubowiak, A. J.
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B. L.
    Wong, A. F.
    Orlowski, R. Z.
    Jagannath, S.
    [J]. LEUKEMIA, 2013, 27 (12) : 2351 - 2356
  • [43] Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
    Vii, Ravi
    Kaufman, Jonathan L.
    Jakubowiak, Andrzej J.
    Wang, Michael
    Jagannath, Sundar
    Kukreti, Vishal
    McDonagh, Kevin T.
    Alsina, Melissa
    Bahlis, Nizar J.
    Belch, Andrew R.
    Reu, Frederic J.
    Gabrail, Nashat Y.
    Matous, Jeffrey
    Vesole, David H.
    Orlowski, Robert Z.
    Wear, Sandra
    Kunkel, Lori
    Wong, Alvin F.
    Lee, Peter
    Stewart, Keith
    [J]. BLOOD, 2011, 118 (21) : 369 - 370
  • [44] Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Hussein, M. A.
    Richardson, P. G.
    Jagannath, S.
    Singhal, S.
    Bensinger, W.
    Knight, R.
    Zeldis, J. B.
    Yu, Z.
    Olesnyckyj, M.
    Anderson, K. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Trappe, Ralf
    Riess, Hanno
    Babel, Nina
    Hummel, Manfred
    Lehmkuhl, Hans
    Jonas, Sven
    Anagnostopoulos, Ioannis
    Papp-Vary, Matthias
    Reinke, Petra
    Hetzer, Roland
    Doerken, Bernd
    Oertel, Stephan
    [J]. TRANSPLANTATION, 2007, 83 (07) : 912 - 918
  • [46] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
    Buckwalter, M
    Dowell, JA
    Korth-Bradley, J
    Gorovits, B
    Mayer, PR
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 873 - 880
  • [47] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review
    Harrison, SJ
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 104 - 105
  • [48] Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)
    Hantel, Andrew
    Khan, Niloufer
    Larson, Richard A.
    Godley, Lucy A.
    Thirman, Michael J.
    Artz, Andrew
    Odenike, Olatoyosi
    Liu, Hongtao
    Churpek, Jane E.
    King, Darren
    Rich, Elizabeth
    Choi, Kwang Jin
    Knoebel, Randall W.
    Stock, Wendy
    [J]. BLOOD, 2015, 126 (23)
  • [49] CARFILZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
    Uysal, A.
    Ozkan, M. Comert
    Soyer, N. Akad
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    Saydam, G.
    [J]. LEUKEMIA RESEARCH, 2016, 49 : S29 - S30
  • [50] Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
    Harvey, R. Donald
    Lonial, Sagar
    Patel, Priti
    McCulloch, Leanne
    Niesvizky, Ruben
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345